tiprankstipranks

Vericel’s Strong Performance and Growth Potential Justify Buy Rating

Vericel’s Strong Performance and Growth Potential Justify Buy Rating

Canaccord Genuity analyst Caitlin Cronin has maintained their bullish stance on VCEL stock, giving a Buy rating today.

Don’t Miss TipRanks’ Half-Year Sale

Caitlin Cronin has given her Buy rating due to a combination of factors that highlight Vericel’s strong performance and future potential. The company reported impressive quarterly results, surpassing revenue expectations and demonstrating robust growth in its MACI segment. The launch of Arthro has shown promising early indicators, with a significant number of surgeons trained and surgeries scheduled, suggesting a successful market penetration strategy.
Cronin also notes that while there were some shortfalls in Burn Care revenue, the overall outlook remains positive with increasing orders for NexoBrid. Vericel’s conservative revenue guidance, combined with strong margin performance and significant operating leverage, further supports the Buy rating. The company’s strategic focus on expanding its surgeon base and improving treatment outcomes positions it well for continued growth and cash generation, making it an attractive investment opportunity.

In another report released today, Citi also maintained a Buy rating on the stock with a $60.00 price target.

VCEL’s price has also changed slightly for the past six months – from $53.560 to $49.620, which is a -7.36% drop .

Disclaimer & DisclosureReport an Issue

1